IMV Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- IMV Inc. operates as a clinical-stage immuno-oncology biopharmaceutical company headquartered in Dartmouth, Canada, founded in 2000. The company develops a portfolio of therapies based on its proprietary DPX immune-educating technology platform, which programs immune cells in vivo. Its core products include DPX-based immunotherapies such as maveropepimut-S targeting survivin-expressing cells and currently in Phase II clinical trials for diffuse large B cell lymphoma, ovarian cancer, bladder, liver, and MSI-H solid tumors, as well as in Phase I trials for breast cancer. IMV also develops DPX-SurMAGE for bladder cancer in Phase I trials, and therapeutic candidates DPX-COVID-19 and DPX-RSV for infectious diseases, reflecting a broad pipeline in oncology and infectious disease treatment areas. Key recent corporate developments include the acquisition of IMV’s entire portfolio of discovery, preclinical, and clinical-stage assets by BioVaxys Technology Corp. in February 2024. This transaction included IMV’s intellectual property and clinical-stage programs, enabling BioVaxys to expand its oncology and infectious disease product offerings. Prior to this, IMV was formerly known as Immunovaccine Inc., changing its name in May 2018 to IMV Inc. The company has focused on strategic clinical development and partnerships to advance its immune therapy candidates. IMV targets solid tumor and hematological cancer markets, alongside infectious disease applications, positioning itself in the biotechnology and health care industry segments. Geographic operations are primarily focused in North America, with its clinical studies and corporate headquarters in Canada. IMV’s research and development efforts underpin its position as a clinical-stage biopharmaceutical innovator with a specialized immuno-oncology and infectious disease pipeline based on its DPX platform technology. The company’s products are tailored for patients requiring novel immunotherapies in oncology and infectious diseases. In summary, IMV Inc. is a Canadian clinical-stage biotechnology company specializing in immune-educating therapeutics based on its DPX platform, actively advancing multiple candidates through clinical trials in oncology and infectious diseases, and recently transferred its assets to BioVaxys Technology Corp. as part of a strategic acquisition completed in early 2024. This positions the company and its assets within a broader biopharmaceutical development framework focused on immunotherapies and innovative treatments. This description integrates details from IMV’s clinical-stage immunotherapy pipeline, recent major asset acquisition, founding and headquarters information, and product-specific development focus.
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.
IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process
IMV Receives NASDAQ Delisting Notice
Horizon Technology Finance Announces First Quarter 2023 Financial Results
IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
IMV Inc. Announces Changes to Its Board of Directors
IMV Inc. (IMV) Q4 2022 Earnings Call Transcript
IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023
IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial
IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S
IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL
IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split
IMV Shareholders Approve Reverse Stock Split at 88%
IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities
IMV, Inc. (IMV) Q3 2022 Earnings Call Transcript